Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Monjuvi
Pharma
ASCO: Incyte positions Monjuvi combo for first-line DLBCL
Incyte believes a consistent PFS benefit across patient subgroups will give its seven-drug Monjuvi combo an edge over a Polivy regimen by Roche.
Angus Liu
May 30, 2026 8:00am
Incyte to seek FDA approval for Monjuvi in front-line DLBCL
Jan 5, 2026 10:40am
JPM25: Incyte plans to turn 'a lot of cards' in 2025, CEO says
Jan 22, 2025 2:38pm
Incyte's Monjuvi proves its worth in follicular lymphoma
Nov 25, 2024 3:20pm
Incyte eyes upcoming launches as Jakafi's patent cliff nears
Oct 29, 2024 5:07pm
Incyte eyes label expansion for Monjuvi after phase 3 win
Aug 16, 2024 11:23am
